Abstract
Purpose: :
In diabetes, angiogenesis is abnormal, contributing to proliferative retinopathy. Kallistatin, a 60KD glycoprotein serine protease inhibitor (also known as serpin a4 and kallikrein-binding protein) is produced mainly in the liver and may be involved in diabetic microvascular complications. The purpose of this study is to measure serum kallistatin levels in Type 1 diabetic patients in the context of diabetic complications such as retinopathy and renal disease.
Methods: :
Human serum kallistatin was quantified by a sandwich enzyme-linked immunosorbent assay in a cross-sectional study of 116 Type 1 diabetic patients (including 50 with and 66 without diabetic complications) and 29 non-diabetic controls. These data were then statistically analyzed with respect to clinical status and measures of oxidative stress and inflammation.
Results: :
Human serum kallistatin was quantified by a sandwich enzyme-linked immunosorbent assay in a cross-sectional study of 116 Type 1 diabetic patients (including 50 with and 66 without diabetic complications) and 29 non-diabetic controls. These data were then statistically analyzed with respect to clinical status and measures of oxidative stress and inflammation.
Conclusions: :
Kallistatin levels are increased in Type 1 diabetic patients with microvascular complications and with hypertension, and correlate with poor renal and vascular health.
Keywords: diabetes • diabetic retinopathy • clinical (human) or epidemiologic studies: outcomes/complications